BI 144807

Drug Profile

BI 144807

Alternative Names: BI-144807

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim Pharmaceuticals
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Allergic rhinitis; Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis(In volunteers) in Germany (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in United Kingdom (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Germany (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top